Treatment of Slow‐Flow After Primary Percutaneous Coronary Intervention With Flow‐Mediated Hyperemia: The Randomized RAIN‐FLOW Study
Journal of the American Heart Association · 2023
DOI: 10.1161/jaha.123.030285 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Josep Gomez-Lara und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitari de Bellvitge, Institut d' Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, L' Hospitalet de Llobregat B…. Hauptthemen laut MEDLINE: Hyperemia, Myocardial Infarction, Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
ST‐segment–elevation myocardial infarction complicated with no reflow after primary percutaneous coronary intervention is associated with adverse outcomes. Although several hyperemic drugs have been shown to improve the Thrombolysis in Myocardial Infarction flow, optimal treatment of no reflow remains unsettled. Saline infusion at 20 mL/min via a dedicated microcatheter causes (flow‐mediated) hyperemia. The objective is to compare the efficacy of pharmacologic versus flow‐mediated hyperemia in patients with ST‐segment–elevation myocardial infarction complicated with no reflow. Methods and Results In the RAIN‐FLOW (Treatment of Slow‐Flow After Primary Percutaneous Coronary Intervention With Flow‐Mediated Hyperemia) study, 67 patients with ST‐segment–elevation myocardial infarction and no reflow were randomized to receive either pharmacologic‐mediated hyperemia with intracoronary adenosine or nitroprusside (n=30) versus flow‐mediated hyperemia (n=37). The angiographic corrected Thrombolysis in Myocardial Infarction frame count and the minimal microcirculatory resistance, as assessed with intracoronary pressure‐thermistor wire, dedicated microcatheter, and thermodilution techniques, were compared after study interventions. Both Thrombolysis in Myocardial Infarction frame count(40.2±23.1 versus 39.2±20.7; P =0.858) and minimal microcirculatory resistance (753.6±661.5 versus 993.3±740.8 Wood units; P =0.174) were similar between groups. Thrombolysis in Myocardial Infarction 3 flow was observed in 26.7% versus 27.0% ( P =0.899). Flow‐mediated hyperemia showed 2 different thermodilution patterns during saline infusion indicative of the severity of the no reflow phenomenon. In‐hospital death and nonfatal heart failure were observed in 10.4% and 26.9%, respectively.
Conclusions
Both treatments showed similar (and limited) efficacy restoring coronary flow. Flow‐mediated hyperemia with thermodilution pattern assessment allowed the simultaneous characterization of the no reflow degree and response to hyperemia. No reflow was associated with a high rate of adverse outcomes. Further research is warranted to prevent and to treat no reflow in patients with ST‐segment–elevation myocardial infarction. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04685941.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hospital Universitari de Bellvitge, Institut d' Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, L' Hospitalet de Llobregat Barcelona Spain.
- Hospital Universtiario La Princesa, Instituto de Investigación Sanitaria-IP (IIS-IP), CIBER-CV Madrid Spain.
- Hospital Puerta del Mar Cádiz Spain.
- Hospital Clínic i Provincial de Barcelona Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain.
ORCID-Profile: Josep Gomez-Lara, Fernando Rivero, Rafael Romaguera, Ana Marcano, Luis Teruel, Salvatore Brugaletta, Fernando Alfonso, Joan-Antoni Gomez-Hospital
Zitieren
APA
Gomez-Lara, J., Gracida, M., Rivero, F., Gutiérrez-Barrios, A., Muntané-Carol, G., Romaguera, R., Fuentes, L., Marcano, A., Roura, G., Ferreiro, J. L., Teruel, L., Brugaletta, S., Alfonso, F., Comín-Colet, J., & Gomez-Hospital, J. A. (2023). Treatment of Slow‐Flow After Primary Percutaneous Coronary Intervention With Flow‐Mediated Hyperemia: The Randomized RAIN‐FLOW Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.030285
Vancouver
Gomez-Lara J, Gracida M, Rivero F, Gutiérrez-Barrios A, Muntané-Carol G, Romaguera R, et al. Treatment of Slow‐Flow After Primary Percutaneous Coronary Intervention With Flow‐Mediated Hyperemia: The Randomized RAIN‐FLOW Study. Journal of the American Heart Association. 2023. doi:10.1161/jaha.123.030285
BibTeX
@article{GomezLara2023,
author = {Gomez-Lara, Josep and Gracida, Montserrat and Rivero, Fernando and Gutiérrez-Barrios, Alejandro and Muntané-Carol, Guillem and Romaguera, Rafael and Fuentes, Lara and Marcano, Ana and Roura, Gerard and Ferreiro, José Luis and Teruel, Luis and Brugaletta, Salvatore and Alfonso, Fernando and Comín-Colet, Josep and Gomez-Hospital, Joan-Antoni},
title = {Treatment of Slow‐Flow After Primary Percutaneous Coronary Intervention With Flow‐Mediated Hyperemia: The Randomized RAIN‐FLOW Study},
journal = {Journal of the American Heart Association},
year = {2023},
doi = {10.1161/jaha.123.030285}
}
EUVIMED